Intravenous immunoglobulin (IVIg) therapy has been suggested as a potential treatment
option for hospitalised COVID‐19 patients. The aim of this systematic review and meta …

Abstract The coronavirus disease‐19 (COVID‐19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) challenged globally with its morbidity …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has become a huge obstacle
to the health system due to the high rate of contagion. It is postulated that intravenous …

Abstract Severe coronavirus disease 2019 (COVID-19) caused by the Severe Acute
Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is characterized by an unpredictable …

Background: Although several therapeutic strategies have been investigated, the optimal
treatment approach for patients with coronavirus disease (COVID-19) remains to be …

Background The clinical benefits of high-dose intravenous immunoglobulin (IVIg) in treating
COVID-19 remained controversial. Methods We systematically searched databases up to …

Background During the COVID-19 pandemic, different treatments have been used in
critically ill patients. Using intravenous immunoglobulin (IVIG) has been suggested in …

Background The benefits of intravenous immunoglobulin administration are controversial for
critically ill COVID-19 patients. Methods We analyzed retrospectively the effects of …

Background The clinical efficacy and safety of intravenous immunoglobulin (IVIg) treatment
for COVID-19 remain controversial. This study aimed to map the current status and gaps of …

Background and purpose: Though controversial, many clinical trials have been conducted to
evaluate the efficacy of intravenous immunoglobulins (IVIG) in COVID-19 cases. Therefore …